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Purpose: To develop and validate the English version of the Satisfaction Questionnaire for 
Osteoporosis Prevention (SQOP) in Malaysia.
Methods: The SQOP was modified from the Osteoporosis Patient Satisfaction Questionnaire 
and developed based on literature review and patient interviews. Face and content validity were 
established via an expert panel. The SQOP consists of two sections: clinical services and types 
of counseling. There were 23 items in total, each with a five-point Likert-type response. Satisfac-
tion score was calculated by converting the total score to a percentage. A higher score indicates 
higher satisfaction. English speaking, non-osteoporotic, postmenopausal women aged 50 years 
were included in the study. Participants were randomized to either the control or intervention 
group. Intervention participants were provided counseling, whereas control participants received 
none. Participants answered the SQOP at baseline and 2 weeks later.
Results: A total of 140 participants were recruited (control group: n=70; intervention group: 
n=70). No significant differences were found in any demographic aspects. Exploratory factor 
analysis extracted seven domains. Cronbach’s α for the domains ranged from 0.531–0.812. All 
23 items were highly correlated using Spearman’s correlation coefficient 0.469–0.996 (P0.05), 
with no significant change in the control group’s overall test–retest scores, indicating that the 
SQOP achieved stable reliability. The intervention group had a higher score than the control 
group (87.91±5.99 versus 61.87±8.76; P0.05), indicating that they were more satisfied than 
control participants. Flesch reading ease was 62.9.
Conclusion: The SQOP was found to be a valid and reliable instrument for assessing patients’ 
satisfaction towards an osteoporosis screening and prevention service in Malaysia.
Keywords: patient satisfaction, randomized controlled trial, postmenopausal women, 
screening
Introduction
Patient satisfaction may potentially be used to evaluate current preventive efforts 
and to predict patients’ adherence to preventive advice.1 The shift from health care 
provider-centered care to a more patient-centered care emphasizes the need to evaluate 
humanistic outcomes such as patient satisfaction.2 The rating of satisfaction by patients 
is a personal evaluation of health care services and providers.3,4 Patient satisfaction 
serves as an important determinant of the viability and sustainability of health care 
services.5
Due to the asymptomatic nature of osteoporosis, women who have osteoporosis are 
often not aware that they are at an increased risk of sustaining a fracture.6 Prevention 
measures and screening that aid in early detection are the most cost-effective ways to 
reduce the number of hospital admissions due to osteoporotic fractures. Evidence shows 
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that satisfied patients are more likely to continue using health 
care services, value and maintain relationships with health 
care providers, follow the advice of the health care profes-
sionals, adhere to treatment, and have better health outcomes, 
which in this case is a reduction in fracture rates.1,7
Evaluating satisfaction can also assist health care pro-
fessionals to provide health care services more effectively. 
Patient evaluations will help identify patients’ needs, per-
ceptions, concerns, and areas of service failure. This in turn 
may encourage health care providers to be accountable for 
the quality of service delivered which ensures continuous 
monitoring and improvement in health care delivery.8
A search of published literature found several randomized 
controlled trials for osteoporosis screening services. These 
randomized controlled trials were conducted by various 
health care professionals such as primary care physicians,9,10 
orthopedic surgeons,10,11 pharmacists,12–14 and nurses.15 All 
interventions demonstrated a positive effect towards bone 
mineral density scanning and osteoporosis treatment post 
fracture.9–15 However, only one study assessed patient satis-
faction, highlighting the fact that many studies did not assess 
patient satisfaction as an outcome.16
A validated tool is necessary as it ensures the validity and 
the reliability of the results. Validity refers to the question-
naire measuring the objective it was designed to measure. 
Reliability refers to the ability of the questionnaire to produce 
the same results under the same conditions. Three tools have 
been developed globally to assess satisfaction pertaining to 
osteoporosis and its treatment,17–19 two of which were devel-
oped and validated in the US17,18 and one was developed in 
Malaysia.19 However, these satisfaction tools were not suit-
able to assess the satisfaction of patients from an osteoporosis 
screening and prevention program, as their focus was on 
osteoporosis and its treatment.17–19 To date, no instrument has 
been developed and validated specifically to assess patients’ 
satisfaction towards an osteoporosis screening and prevention 
program in Malaysia. Therefore, the aim of this study was to 
develop and validate the English version of the Satisfaction 
Questionnaire for Osteoporosis Prevention (SQOP) to evalu-
ate patients’ satisfaction towards an osteoporosis screening 
and prevention program in Malaysia.
Methods
Development of the sQOP
Despite Malay being the national language of Malaysia, 
postmenopausal women aged 50 years residing in Malaysia 
are more fluent in English, as schooling was only conducted 
in the English language back then. Hence, the SQOP was 
developed in English based on modifications from the 
Osteoporosis Patient Satisfaction Questionnaire (OPSQ) and 
findings from a qualitative study that examined the barriers 
and needs towards an osteoporosis screening and prevention 
service in Malaysia.
Of the 16 items in the OPSQ, nine items were removed. 
Eight of these items were on satisfaction related to osteopo-
rosis medication, whilst one item was on a follow-up visit. 
Four items from the OPSQ were rephrased. In item two, 
the word “session” was used instead of “appointment” as 
appointments were not made with the participants. The ques-
tion in item seven – “How useful was the service provided 
by the pharmacist in this study?” – was considered leading 
and was rephrased to “How would you rate the advice given 
by the pharmacist?”. The word “overall” was added to item 
nine – “How would you rate the overall quality of service that 
was given by the pharmacist to you?” – to make the question 
more specific. The original question for item 18 – “How 
would you rate your understanding of osteoporosis since you 
participated in the study?” – was modified to “How would 
you rate your understanding of osteoporosis now?” as the 
questionnaire was going to be used in clinical practice after 
completion of the study. Three items were retained from the 
OPSQ without any modifications.
Results from the qualitative findings suggest that the fol-
lowing domains may influence patients’ satisfaction when 
utilizing an osteoporosis screening and prevention service: 
outcomes/efficacy, accessibility/convenience, technical 
quality, interpersonal relationship, finance, and continuity. 
A literature search noted that these domains were similar 
to those recommended by Ware et al except that Ware et al 
had an additional domain (ie, physical condition)4. Hence, 
the domain of physical condition was also included in the 
SQOP. Therefore, 16 new items were added. The final SQOP 
consisted of 23 items, and was divided into seven domains. 
Each item had a five-point Likert-type response. Please refer 
to the Supplementary material for the full questionnaire.
Validation of the sQOP
The validation process was a prospective, randomized con-
trolled trial conducted from September to December 2013 
at a primary care clinic of a tertiary hospital in Malaysia. 
Institutional Medical Ethics approval was obtained prior to 
the study (reference number 920.27).
Face and content validity of the SQOP was established 
via consultation with an expert panel (a consultant endocri-
nologist and four pharmacists with many years of research 
and clinical experience). Comprehension of the questionnaire 
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was tested on ten postmenopausal women who understood 
English. This involved asking the participants for their opin-
ions about the phrasing, format, and content of the instrument. 
This resulted in the change of item eight from “Has the advice 
given by the pharmacist affected your life in general?” to 
“How would you rate the advice given by the pharmacist?” 
as participants commented that it was difficult to gauge the 
effect of newly given advice.
Participants
To validate the final version of the SQOP, 140 postmeno-
pausal women were recruited. Postmenopausal women 
aged 50 years and above who had not been diagnosed with 
osteoporosis/osteopenia were included. Women who did not 
speak English were excluded. Sample size was calculated 
based on a 5:1 subject-to-item ratio for factor analysis.20 
Allowing for a 20% loss at follow-up, the total number of 
participants required was 70 in each arm.
intervention
Intervention participants received 30 minutes of verbal 
counseling and an osteoporosis booklet. Topics covered 
during the counseling session were the definition of osteo-
porosis, consequences of untreated osteoporosis, risk factors 
for osteoporosis, the role of the bone mineral density scan 
(its function, what the results mean, accessibility, and the 
frequency a patient has to go for a bone mineral density 
scan), other tests used in osteoporosis screening (quantitative 
ultrasound scanning, X-ray, blood test, and the Osteoporosis 
Screening Tool for Asians), lifestyle changes (calcium intake, 
vitamin D intake, weight bearing exercise, and fall preven-
tion), and treatment of osteoporosis.
Control participants received standard care. Standard 
care involved a regular visit to the doctor. Any counseling 
on osteoporosis by the doctor was opportunistic and at the 
doctors’ discretion.
Procedure
The researcher screened for potential participants by using 
a 1:2 systematic random sampling procedure (Figure 1). 
Participants were recruited in the clinic’s waiting area while 
they were waiting to see their doctor. Randomization of 
participants to either the control or intervention group was 
performed by drawing pieces of paper stating control or 
intervention from a bag while participants were filling out 
the demographic form. Participants answered the question-
naire themselves. However, for those who experienced some 
difficulty in reading the questions themselves, the researcher 
read the questions out for them and assisted them in filling 
in the questionnaire. The researcher ensured that all ques-
tions had been answered. Most participants required about 
5 minutes to complete the questionnaire.
Data analysis
All data was entered into IBM® SPSS® version 20 (IBM 
Corporation, Armonk, NY, USA). Each item had a five-point 
Likert-type response. One indicates the lowest satisfaction for 
that item and five indicates the highest satisfaction. Scores 
ranged from 30–150, and were converted to a percentage, 
ranging from 0%–100%. Zero indicates the lowest level 
of satisfaction, whilst 100 indicates the highest. Baseline 
demographic data of the control and intervention group 
was compared using the chi-square test for categorical 
variables or the independent t-test for continuous variables. 
Nonparametric tests were used since the data obtained was 
not of normal distribution. A P-value 0.05 was considered 
statistically significant.
Face and content validity were used to ascertain ana-
lytical validity. Exploratory factor analysis (EFA) was used 
Figure 1 The validation procedure of the satisfaction Questionnaire for Osteoporosis 
Prevention.
Abbreviation: sQOP, satisfaction Questionnaire for Osteoporosis Prevention.
Informed consent and baseline information obtained
Randomly allocated
Intervention group
N=70
Control group
N=70
Counseling session plus
osteoporosis booklet 
provided
First follow-up
(2 weeks later)
Baseline
Counseling session (by phone) 
plus osteoporosis booklet (via 
mail) provided 
SQOP was administered over 
the phone
SQOP was administered over 
the phone
SQOP was administeredSQOP was administered
Number of participants recruited (n=140)
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to determine empirical validity. EFA was performed to 
provide information about the validity of the items within 
each domain and to explore the appropriateness of the fac-
tor structure of the current questionnaire. It is important 
to note that the control group was not required to answer 
items 19–23 as these items were specifically assessing the 
satisfaction of the intervention conducted. However, all 
items (ie, items 1–23) in the EFA were included for two 
reasons. Firstly, although the control group did not answer 
items 19–23, it still represented one of the seven domains. 
Secondly, if control participants were excluded from the 
EFA, then the minimum number of participants required 
would not have been satisfied (ie, 100 participants) as there 
were more than six factors present.21 The extraction method 
used was maximum likelihood and the rotation method was 
promax. To determine how many factors were retained, 
a criterion of eigenvalue 1.0 was used. Corrected  item-total 
correlations were used to identify items which did not mea-
sure the same main component as the other items. A value 
of 0.3 indicates that the item is measuring a different 
component from the scale as a whole.
The mean score ± standard deviation was calculated 
for each item. Cronbach’s α and test–retest were used to 
assess the internal consistency and stable reliability of the 
questionnaire, respectively. The results for the interven-
tion and control groups were combined to test for internal 
Table 1 Baseline demographic characteristics of participants
Characteristics Control  
(n=70)
Intervention  
(n=70)
χ2/t-valuea,c P-value
Mean age ± sD, years (range)/median 58.51±7.06 (50–77)/56.00 60.57±7.26 (50–77)/60.00 -1.700 0.091
Age range, n (%)
65 years
65 years
56 (80.0)
14 (20.0)
50 (71.4)
20 (28.6)
1.398 0.237
ethnicity, n (%)
Malay
chinese
indian
Othersb
13 (18.6)
31 (44.3)
24 (34.3)
2 (2.9)
17 (24.3)
29 (41.4)
19 (27.1)
5 (7.1)
2.467 0.495
Mean BMi ± sD/median 25.33±6.50/23.52 25.32±5.75/23.63 0.003 0.997
BMi, n (%)
18.5 (underweight)
18.5–24.9 (normal)
25.0–29.9 (overweight)
30.0 (obese)
5 (7.1)
37 (52.9)
17 (24.3)
11 (15.7)
5 (7.1)
32 (45.7)
19 (27.1)
14 (20.0)
0.833 0.841
level of education, n (%)
Primary (6 years of education) 4 (5.7) 3 (4.3)
1.727 0.631
secondary (11–13 years of education) 33 (47.1) 28 (40.0)
Diploma/technical (12–14 years of education) 15 (21.4) 14 (20.0)
Tertiary/postgraduate (15–21 years of education) 18 (25.7) 25 (35.7)
Notes: aThe chi-square test was used for all categorical variables, whilst the independent t-test was used for all continuous variables. bincludes four eurasians, one Portuguese, 
and one Thai. cFisher’s exact test was used as the number of cells with an expected count of less than five was more than 20% of the total number of cells.
Abbreviations: BMi, body mass index; sD, standard deviation.
Table 2 eigenvalue of the satisfaction Questionnaire for Osteoporosis Prevention and the proportion of variance explained using 
promax and maximum likelihood
Factor Before rotation After rotation 
Eigenvalue Percentage 
of variances
Cumulative percentage 
of variances
Eigenvalue Percentage 
of variances
Cumulative percentage 
of variances
Factor 1 3.520 15.30 15.30 7.548 32.82 32.82
Factor 2 2.981 12.96 28.27 2.908 12.64 45.46
Factor 3 2.364 10.28 38.54 1.977 8.56 54.05
Factor 4 2.363 10.27 48.81 1.768 7.69 61.74
Factor 5 2.287 9.94 58.76 1.523 6.62 68.36
Factor 6 1.631 1.09 65.85 1.354 5.89 74.25
Factor 7 1.122 4.88 70.73 1.112 4.84 79.09
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reliability (Cronbach’s α). Cronbach’s α 0.70 indicates 
good internal reliability.22 Microsoft Office® Word® 2007 
(Microsoft Corporation, Redmond, WA, USA) was used 
to calculate the Flesch reading ease. Flesch reading ease 
was performed to assess the reading comprehension level 
necessary to understand the written document. An average 
document should have a score of 60–70.23
External validity was determined using discriminant 
validity, which was performed on the control and interven-
tion groups to assess if the SQOP was able to differentiate 
between the satisfaction levels of the two groups. Since, 
the control group was not required to answer items 19–23, 
the total score of both the control and intervention groups 
were changed into percentages. The Mann–Whitney U-test 
was then used to analyze the discriminant validity between 
the control and intervention groups using their percentages. 
To assess test–retest reliability, the Wilcoxon signed-rank 
test and Spearman’s correlation were used.
Results
A total of 173 participants were approached: 33 declined 
and 140 participants (80.9%) were recruited (control group: 
n=70; intervention group: n=70). No significant differences 
were found between the control group and intervention group 
in all demographic aspects (Table 1).
Factor analysis and psychometric 
properties of the sQOP
EFA extracted seven domains with a criterion of eigen-
value 1.0. This explains the 79.1% of the cumulative vari-
ances. The eigenvalue and the proportion of variance explained 
are shown in Table 2. The factor loading of the items to each 
factor are shown in Table 3 (0.118–0.977). All items had a fac-
tor loading of 0.3 except item 17, which had a factor loading 
of 0.118. However, this item was maintained due to its impor-
tance based on findings from the qualitative study. Correlations 
between the factors resulting from the rotation were similar and 
the residuals ranged from -0.184–0.167 (Table 4).
The items representing each domain are shown in Table 5. 
Cronbach’s α of each domain are shown in Table 5 ranging 
from 0.531–0.812. All items had a corrected item-total cor-
relation of 0.3. Flesch reading ease was 62.9.
At retest, eight participants (5.7%) dropped out of the 
study: three (2.1%) were overseas and five (3.6%) could not 
be contacted, leaving 132 (94.3%) at retest. Results from the 
control group and intervention group were analyzed separately. 
All test–retest scores were significantly correlated for both the 
control (P0.05) and intervention (P0.05) group. No sig-
nificant difference was found for all items in the control group 
except items five and six (Table 6). For the intervention group, 
no significant difference was found for all items except items 
Table 3 Factor loading of items in the satisfaction Questionnaire for Osteoporosis Prevention
Items Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6  Factor 7
Q1 0.037 0.339 0.283 0.034 0.373 0.417 0.423
Q2 0.428 0.304 0.340 0.108 0.040 0.914 0.163
Q3 0.078 0.392 0.141 0.063 0.977 0.078 0.004
Q4 0.109 0.462 0.277 0.173 0.379 0.166 -0.120
Q5 0.122 0.046 -0.004 0.188 -0.058 0.082 0.451
Q6 -0.169 0.125 0.052 -0.035 0.826 -0.130 -0.001
Q7 0.502 0.427 0.298 0.387 -0.079 0.545 0.170
Q8 0.451 0.199 0.593 0.462 0.041 0.555 0.222
Q9 0.590 0.703 0.472 0.114 0.430 0.153 -0.035
Q10 0.761 0.232 0.403 0.049 0.066 0.258 0.008
Q11 0.788 0.225 0.603 0.433 0.036 0.472 0.384
Q12 0.519 0.250 0.383 0.367 -0.063 0.378 0.110
Q13 0.530 0.622 0.669 0.434 0.080 0.565 0.430
Q14 0.714 0.318 -0.035 0.338 -0.053 0.562 0.240
Q15 0.841 0.400 0.350 0.520 -0.019 0.365 0.210
Q16 0.432 0.315 0.563 0.910 0.164 0.094 0.010
Q17 -0.311 0.037 -0.633 -0.239 0.118 -0.112 0.106
Q18 0.363 0.675 0.338 0.164 0.227 0.404 0.243
Q19 0.331 0.701 0.159 0.178 0.257 -0.017 -0.286
Q20 -0.014 0.762 0.027 0.135 0.125 0.265 0.355
Q21 0.384 0.669 0.771 0.467 0.287 0.358 0.175
Q22 0.191 0.288 0.351 0.924 0.084 0.368 0.536
Q23 0.308 0.660 0.818 0.406 0.401 0.475 0.452
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Table 4 correlations between the factors resulting from the rotation using promax and maximum likelihood
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23
Correlation
Q1 10.000 0.320 0.351 0.336 -0.095 0.196 0.167 0.221 0.242 0.142 0.221 0.221 0.238 0.150 0.019 0.000 0.000 0.360 0.074 0.216 0.353 0.188 0.381
Q2 0.320 10.000 0.104 0.231 -0.116 -0.131 0.526 0.539 0.240 0.367 0.411 0.382 0.470 0.515 0.317 0.021 -0.207 0.368 0.084 0.109 0.334 0.078 0.367
Q3 0.351 0.104 10.000 0.390 -0.055 0.808 -0.016 0.038 0.435 0.082 0.038 -0.035 0.064 0.087 0.051 0.174 0.190 0.247 0.306 0.152 0.242 0.109 0.331
Q4 0.336 0.231 0.390 10.000 -0.110 0.170 0.193 0.154 0.448 -0.082 0.000 0.139 0.127 0.044 0.202 0.248 -0.195 0.131 0.515 0.140 0.451 0.109 0.378
Q5 -0.095 -0.116 -0.055 -0.110 10.000 -0.136 0.198 0.137 0.021 -0.004 0.239 0.013 0.228 0.211 0.226 0.082 0.150 0.081 -0.115 0.051 -0.027 0.317 0.125
Q6 0.196 -0.131 0.808 0.170 -0.136 10.000 -0.155 -0.101 0.147 -0.090 -0.101 -0.122 -0.167 -0.161 -0.132 0.076 0.298 -0.143 0.084 0.031 0.155 0.047 0.192
Q7 0.167 0.526 -0.016 0.193 0.198 -0.155 10.000 0.471 0.353 0.198 0.471 0.462 0.486 0.436 0.542 0.317 -0.113 0.316 0.352 0.237 0.348 0.324 0.366
Q8 0.221 0.539 0.038 0.154 0.137 -0.101 0.471 10.000 0.243 0.438 0.576 0.440 0.427 0.283 0.386 0.481 -0.449 0.337 0.051 -0.046 0.420 0.429 0.522
Q9 0.242 0.240 0.435 0.448 0.021 0.147 0.353 0.243 10.000 0.521 0.398 0.341 0.532 0.288 0.524 0.301 -0.218 0.435 0.574 0.351 0.557 0.031 0.508
Q10 0.142 0.367 0.082 -0.082 -0.004 -0.090 0.198 0.438 0.521 10.000 0.666 0.531 0.350 0.511 0.478 0.184 -0.240 0.431 0.204 -0.064 0.375 -0.046 0.280
Q11 0.221 0.411 0.038 0.000 0.239 -0.101 0.471 0.576 0.398 0.666 10.000 0.440 0.603 0.524 0.759 0.481 -0.449 0.337 0.051 -0.046 0.420 0.429 0.522
Q12 0.221 0.382 -0.035 0.139 0.013 -0.122 0.462 0.440 0.341 0.531 0.440 10.000 0.411 0.452 0.411 0.374 -0.272 0.189 0.115 -0.017 0.509 0.292 0.316
Q13 0.238 0.470 0.064 0.127 0.228 -0.167 0.486 0.427 0.532 0.350 0.603 0.411 10.000 0.370 0.640 0.455 -0.347 0.559 0.232 0.352 0.697 0.462 0.722
Q14 0.150 0.515 0.087 0.044 0.211 -0.161 0.436 0.283 0.288 0.511 0.524 0.452 0.370 10.000 0.690 0.175 0.144 0.301 0.165 0.207 0.170 0.291 0.148
Q15 0.019 0.317 0.051 0.202 0.226 -0.132 0.542 0.386 0.524 0.478 0.759 0.411 0.640 0.690 10.000 0.513 -0.250 0.285 0.301 0.110 0.397 0.433 0.382
Q16 0.000 0.021 0.174 0.248 0.082 0.076 0.317 0.481 0.301 0.184 0.481 0.374 0.455 0.175 0.513 10.000 -0.416 0.176 0.288 0.021 0.606 0.777 0.507
Q17 0.000 -0.207 0.190 -0.195 0.150 0.298 -0.113 -0.449 -0.218 -0.240 -0.449 -0.272 -0.347 0.144 -0.250 -0.416 10.000 -0.026 -0.025 0.301 -0.289 -0.127 -0.319
Q18 0.360 0.368 0.247 0.131 0.081 -0.143 0.316 0.337 0.435 0.431 0.337 0.189 0.559 0.301 0.285 0.176 -0.026 10.000 0.478 0.562 0.447 0.183 0.447
Q19 0.074 0.084 0.306 0.515 -0.115 0.084 0.352 0.051 0.574 0.204 0.051 0.115 0.232 0.165 0.301 0.288 -0.025 0.478 10.000 0.472 0.395 0.018 0.292
Q20 0.216 0.109 0.152 0.140 0.051 0.031 0.237 -0.046 0.351 -0.064 -0.046 -0.017 0.352 0.207 0.110 0.021 0.301 0.562 0.472 10.000 0.307 0.235 0.372
Q21 0.353 0.334 0.242 0.451 -0.027 0.155 0.348 0.420 0.557 0.375 0.420 0.509 0.697 0.170 0.397 0.606 -0.289 0.447 0.395 0.307 10.000 0.432 0.804
Q22 0.188 0.078 0.109 0.109 0.317 0.047 0.324 0.429 0.031 -0.046 0.429 0.292 0.462 0.291 0.433 0.777 -0.127 0.183 0.018 0.235 0.432 10.000 0.492
Q23 0.381 0.367 0.331 0.378 0.125 0.192 0.366 0.522 0.508 0.280 0.522 0.316 0.722 0.148 0.382 0.507 -0.319 0.447 0.292 0.372 0.804 0.492 1.000
Reproduced correlation
Q1 0.382 0.320 0.351 0.169 0.089 0.242 0.152 0.198 0.213 0.086 0.195 0.086 0.310 0.135 0.089 0.008 0.037 0.289 0.039 0.263 0.271 0.187 0.422
Q2 0.320 0.999 0.104 0.232 -0.115 -0.131 0.526 0.539 0.240 0.367 0.411 0.382 0.469 0.515 0.317 0.021 -0.207 0.368 0.084 0.109 0.334 0.078 0.367
Q3 0.351 0.104 0.999 0.389 -0.055 0.808 -0.016 0.039 0.435 0.083 0.038 -0.035 0.064 0.087 0.051 0.174 0.190 0.246 0.306 0.153 0.243 0.109 0.331
Q4 0.169 0.232 0.389 0.368 -0.150 0.238 0.179 0.159 0.365 0.072 0.027 0.111 0.238 0.040 0.091 0.258 -0.071 0.286 0.397 0.249 0.395 0.108 0.351
Q5 0.089 -0.115 -0.055 -0.150 0.319 -0.046 0.061 0.036 -0.012 0.057 0.250 0.064 0.158 0.213 0.237 0.086 0.099 0.065 -0.123 0.130 -0.002 0.317 0.101
Q6 0.242 -0.131 0.808 0.238 -0.046 0.746 -0.209 -0.087 0.186 -0.095 -0.116 -0.170 -0.124 -0.157 -0.160 0.076 0.186 0.034 0.094 0.004 0.069 0.047 0.170
Q7 0.152 0.526 -0.016 0.179 0.061 -0.209 0.489 0.408 0.318 0.328 0.438 0.383 0.505 0.497 0.493 0.318 -0.173 0.371 0.258 0.255 0.398 0.324 0.365
Q8 0.198 0.539 0.039 0.159 0.036 -0.087 0.408 0.594 0.228 0.347 0.579 0.415 0.522 0.307 0.431 0.480 -0.434 0.235 0.025 -0.047 0.481 0.429 0.501
Q9 0.213 0.240 0.435 0.365 -0.012 0.186 0.318 0.228 0.778 0.517 0.414 0.288 0.504 0.308 0.489 0.302 -0.159 0.518 0.597 0.332 0.565 0.031 0.528
Q10 0.086 0.367 0.083 0.072 0.057 -0.095 0.328 0.347 0.517 0.679 0.641 0.377 0.422 0.455 0.584 0.182 -0.310 0.292 0.203 -0.076 0.309 -0.046 0.292
Q11 0.195 0.411 0.038 0.027 0.250 -0.116 0.438 0.579 0.414 0.641 0.884 0.501 0.627 0.542 0.738 0.480 -0.413 0.306 0.031 -0.060 0.455 0.429 0.516
Q12 0.086 0.382 -0.035 0.111 0.064 -0.170 0.383 0.415 0.288 0.377 0.501 0.370 0.442 0.379 0.480 0.377 -0.296 0.250 0.154 0.043 0.369 0.292 0.338
Q13 0.310 0.469 0.064 0.238 0.158 -0.124 0.505 0.522 0.504 0.422 0.627 0.442 0.753 0.391 0.570 0.455 -0.321 0.515 0.291 0.368 0.672 0.462 0.716
Q14 0.135 0.515 0.087 0.040 0.213 -0.157 0.497 0.307 0.308 0.455 0.542 0.379 0.391 0.836 0.673 0.174 0.076 0.344 0.188 0.205 0.131 0.291 0.134
Q15 0.089 0.317 0.051 0.091 0.237 -0.160 0.493 0.431 0.489 0.584 0.738 0.480 0.570 0.673 0.806 0.515 -0.224 0.374 0.286 0.142 0.412 0.433 0.381
Q16 0.008 0.021 0.174 0.258 0.086 0.076 0.318 0.480 0.302 0.182 0.480 0.377 0.455 0.174 0.515 0.990 -0.418 0.174 0.288 0.020 0.603 0.777 0.507
Q17 0.037 -0.207 0.190 -0.071 0.099 0.186 -0.173 -0.434 -0.159 -0.310 -0.413 -0.296 -0.321 0.076 -0.224 -0.418 0.612 -0.024 0.010 0.290 -0.397 -0.127 -0.335
Q18 0.289 0.368 0.246 0.286 0.065 0.034 0.371 0.235 0.518 0.292 0.306 0.250 0.515 0.344 0.374 0.174 -0.024 0.508 0.422 0.485 0.475 0.184 0.500
Q19 0.039 0.084 0.306 0.397 -0.123 0.094 0.258 0.025 0.597 0.203 0.031 0.154 0.291 0.188 0.286 0.288 0.010 0.422 0.715 0.453 0.433 0.018 0.288
Q20 0.263 0.109 0.153 0.249 0.130 0.004 0.255 -0.047 0.332 -0.076 -0.060 0.043 0.368 0.205 0.142 0.020 0.290 0.485 0.453 0.791 0.329 0.235 0.365
Q21 0.271 0.334 0.243 0.395 -0.002 0.069 0.398 0.481 0.565 0.309 0.455 0.369 0.672 0.131 0.412 0.603 -0.397 0.475 0.433 0.329 0.784 0.432 0.770
Q22 0.187 0.078 0.109 0.108 0.317 0.047 0.324 0.429 0.031 -0.046 0.429 0.292 0.462 0.291 0.433 0.777 -0.127 0.184 0.018 0.235 0.432 10.000 0.492
Q23 0.422 0.367 0.331 0.351 0.101 0.170 0.365 0.501 0.528 0.292 0.516 0.338 0.716 0.134 0.381 0.507 -0.335 0.500 0.288 0.365 0.770 0.492 0.865
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Table 4 correlations between the factors resulting from the rotation using promax and maximum likelihood
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23
Correlation
Q1 10.000 0.320 0.351 0.336 -0.095 0.196 0.167 0.221 0.242 0.142 0.221 0.221 0.238 0.150 0.019 0.000 0.000 0.360 0.074 0.216 0.353 0.188 0.381
Q2 0.320 10.000 0.104 0.231 -0.116 -0.131 0.526 0.539 0.240 0.367 0.411 0.382 0.470 0.515 0.317 0.021 -0.207 0.368 0.084 0.109 0.334 0.078 0.367
Q3 0.351 0.104 10.000 0.390 -0.055 0.808 -0.016 0.038 0.435 0.082 0.038 -0.035 0.064 0.087 0.051 0.174 0.190 0.247 0.306 0.152 0.242 0.109 0.331
Q4 0.336 0.231 0.390 10.000 -0.110 0.170 0.193 0.154 0.448 -0.082 0.000 0.139 0.127 0.044 0.202 0.248 -0.195 0.131 0.515 0.140 0.451 0.109 0.378
Q5 -0.095 -0.116 -0.055 -0.110 10.000 -0.136 0.198 0.137 0.021 -0.004 0.239 0.013 0.228 0.211 0.226 0.082 0.150 0.081 -0.115 0.051 -0.027 0.317 0.125
Q6 0.196 -0.131 0.808 0.170 -0.136 10.000 -0.155 -0.101 0.147 -0.090 -0.101 -0.122 -0.167 -0.161 -0.132 0.076 0.298 -0.143 0.084 0.031 0.155 0.047 0.192
Q7 0.167 0.526 -0.016 0.193 0.198 -0.155 10.000 0.471 0.353 0.198 0.471 0.462 0.486 0.436 0.542 0.317 -0.113 0.316 0.352 0.237 0.348 0.324 0.366
Q8 0.221 0.539 0.038 0.154 0.137 -0.101 0.471 10.000 0.243 0.438 0.576 0.440 0.427 0.283 0.386 0.481 -0.449 0.337 0.051 -0.046 0.420 0.429 0.522
Q9 0.242 0.240 0.435 0.448 0.021 0.147 0.353 0.243 10.000 0.521 0.398 0.341 0.532 0.288 0.524 0.301 -0.218 0.435 0.574 0.351 0.557 0.031 0.508
Q10 0.142 0.367 0.082 -0.082 -0.004 -0.090 0.198 0.438 0.521 10.000 0.666 0.531 0.350 0.511 0.478 0.184 -0.240 0.431 0.204 -0.064 0.375 -0.046 0.280
Q11 0.221 0.411 0.038 0.000 0.239 -0.101 0.471 0.576 0.398 0.666 10.000 0.440 0.603 0.524 0.759 0.481 -0.449 0.337 0.051 -0.046 0.420 0.429 0.522
Q12 0.221 0.382 -0.035 0.139 0.013 -0.122 0.462 0.440 0.341 0.531 0.440 10.000 0.411 0.452 0.411 0.374 -0.272 0.189 0.115 -0.017 0.509 0.292 0.316
Q13 0.238 0.470 0.064 0.127 0.228 -0.167 0.486 0.427 0.532 0.350 0.603 0.411 10.000 0.370 0.640 0.455 -0.347 0.559 0.232 0.352 0.697 0.462 0.722
Q14 0.150 0.515 0.087 0.044 0.211 -0.161 0.436 0.283 0.288 0.511 0.524 0.452 0.370 10.000 0.690 0.175 0.144 0.301 0.165 0.207 0.170 0.291 0.148
Q15 0.019 0.317 0.051 0.202 0.226 -0.132 0.542 0.386 0.524 0.478 0.759 0.411 0.640 0.690 10.000 0.513 -0.250 0.285 0.301 0.110 0.397 0.433 0.382
Q16 0.000 0.021 0.174 0.248 0.082 0.076 0.317 0.481 0.301 0.184 0.481 0.374 0.455 0.175 0.513 10.000 -0.416 0.176 0.288 0.021 0.606 0.777 0.507
Q17 0.000 -0.207 0.190 -0.195 0.150 0.298 -0.113 -0.449 -0.218 -0.240 -0.449 -0.272 -0.347 0.144 -0.250 -0.416 10.000 -0.026 -0.025 0.301 -0.289 -0.127 -0.319
Q18 0.360 0.368 0.247 0.131 0.081 -0.143 0.316 0.337 0.435 0.431 0.337 0.189 0.559 0.301 0.285 0.176 -0.026 10.000 0.478 0.562 0.447 0.183 0.447
Q19 0.074 0.084 0.306 0.515 -0.115 0.084 0.352 0.051 0.574 0.204 0.051 0.115 0.232 0.165 0.301 0.288 -0.025 0.478 10.000 0.472 0.395 0.018 0.292
Q20 0.216 0.109 0.152 0.140 0.051 0.031 0.237 -0.046 0.351 -0.064 -0.046 -0.017 0.352 0.207 0.110 0.021 0.301 0.562 0.472 10.000 0.307 0.235 0.372
Q21 0.353 0.334 0.242 0.451 -0.027 0.155 0.348 0.420 0.557 0.375 0.420 0.509 0.697 0.170 0.397 0.606 -0.289 0.447 0.395 0.307 10.000 0.432 0.804
Q22 0.188 0.078 0.109 0.109 0.317 0.047 0.324 0.429 0.031 -0.046 0.429 0.292 0.462 0.291 0.433 0.777 -0.127 0.183 0.018 0.235 0.432 10.000 0.492
Q23 0.381 0.367 0.331 0.378 0.125 0.192 0.366 0.522 0.508 0.280 0.522 0.316 0.722 0.148 0.382 0.507 -0.319 0.447 0.292 0.372 0.804 0.492 1.000
Reproduced correlation
Q1 0.382 0.320 0.351 0.169 0.089 0.242 0.152 0.198 0.213 0.086 0.195 0.086 0.310 0.135 0.089 0.008 0.037 0.289 0.039 0.263 0.271 0.187 0.422
Q2 0.320 0.999 0.104 0.232 -0.115 -0.131 0.526 0.539 0.240 0.367 0.411 0.382 0.469 0.515 0.317 0.021 -0.207 0.368 0.084 0.109 0.334 0.078 0.367
Q3 0.351 0.104 0.999 0.389 -0.055 0.808 -0.016 0.039 0.435 0.083 0.038 -0.035 0.064 0.087 0.051 0.174 0.190 0.246 0.306 0.153 0.243 0.109 0.331
Q4 0.169 0.232 0.389 0.368 -0.150 0.238 0.179 0.159 0.365 0.072 0.027 0.111 0.238 0.040 0.091 0.258 -0.071 0.286 0.397 0.249 0.395 0.108 0.351
Q5 0.089 -0.115 -0.055 -0.150 0.319 -0.046 0.061 0.036 -0.012 0.057 0.250 0.064 0.158 0.213 0.237 0.086 0.099 0.065 -0.123 0.130 -0.002 0.317 0.101
Q6 0.242 -0.131 0.808 0.238 -0.046 0.746 -0.209 -0.087 0.186 -0.095 -0.116 -0.170 -0.124 -0.157 -0.160 0.076 0.186 0.034 0.094 0.004 0.069 0.047 0.170
Q7 0.152 0.526 -0.016 0.179 0.061 -0.209 0.489 0.408 0.318 0.328 0.438 0.383 0.505 0.497 0.493 0.318 -0.173 0.371 0.258 0.255 0.398 0.324 0.365
Q8 0.198 0.539 0.039 0.159 0.036 -0.087 0.408 0.594 0.228 0.347 0.579 0.415 0.522 0.307 0.431 0.480 -0.434 0.235 0.025 -0.047 0.481 0.429 0.501
Q9 0.213 0.240 0.435 0.365 -0.012 0.186 0.318 0.228 0.778 0.517 0.414 0.288 0.504 0.308 0.489 0.302 -0.159 0.518 0.597 0.332 0.565 0.031 0.528
Q10 0.086 0.367 0.083 0.072 0.057 -0.095 0.328 0.347 0.517 0.679 0.641 0.377 0.422 0.455 0.584 0.182 -0.310 0.292 0.203 -0.076 0.309 -0.046 0.292
Q11 0.195 0.411 0.038 0.027 0.250 -0.116 0.438 0.579 0.414 0.641 0.884 0.501 0.627 0.542 0.738 0.480 -0.413 0.306 0.031 -0.060 0.455 0.429 0.516
Q12 0.086 0.382 -0.035 0.111 0.064 -0.170 0.383 0.415 0.288 0.377 0.501 0.370 0.442 0.379 0.480 0.377 -0.296 0.250 0.154 0.043 0.369 0.292 0.338
Q13 0.310 0.469 0.064 0.238 0.158 -0.124 0.505 0.522 0.504 0.422 0.627 0.442 0.753 0.391 0.570 0.455 -0.321 0.515 0.291 0.368 0.672 0.462 0.716
Q14 0.135 0.515 0.087 0.040 0.213 -0.157 0.497 0.307 0.308 0.455 0.542 0.379 0.391 0.836 0.673 0.174 0.076 0.344 0.188 0.205 0.131 0.291 0.134
Q15 0.089 0.317 0.051 0.091 0.237 -0.160 0.493 0.431 0.489 0.584 0.738 0.480 0.570 0.673 0.806 0.515 -0.224 0.374 0.286 0.142 0.412 0.433 0.381
Q16 0.008 0.021 0.174 0.258 0.086 0.076 0.318 0.480 0.302 0.182 0.480 0.377 0.455 0.174 0.515 0.990 -0.418 0.174 0.288 0.020 0.603 0.777 0.507
Q17 0.037 -0.207 0.190 -0.071 0.099 0.186 -0.173 -0.434 -0.159 -0.310 -0.413 -0.296 -0.321 0.076 -0.224 -0.418 0.612 -0.024 0.010 0.290 -0.397 -0.127 -0.335
Q18 0.289 0.368 0.246 0.286 0.065 0.034 0.371 0.235 0.518 0.292 0.306 0.250 0.515 0.344 0.374 0.174 -0.024 0.508 0.422 0.485 0.475 0.184 0.500
Q19 0.039 0.084 0.306 0.397 -0.123 0.094 0.258 0.025 0.597 0.203 0.031 0.154 0.291 0.188 0.286 0.288 0.010 0.422 0.715 0.453 0.433 0.018 0.288
Q20 0.263 0.109 0.153 0.249 0.130 0.004 0.255 -0.047 0.332 -0.076 -0.060 0.043 0.368 0.205 0.142 0.020 0.290 0.485 0.453 0.791 0.329 0.235 0.365
Q21 0.271 0.334 0.243 0.395 -0.002 0.069 0.398 0.481 0.565 0.309 0.455 0.369 0.672 0.131 0.412 0.603 -0.397 0.475 0.433 0.329 0.784 0.432 0.770
Q22 0.187 0.078 0.109 0.108 0.317 0.047 0.324 0.429 0.031 -0.046 0.429 0.292 0.462 0.291 0.433 0.777 -0.127 0.184 0.018 0.235 0.432 10.000 0.492
Q23 0.422 0.367 0.331 0.351 0.101 0.170 0.365 0.501 0.528 0.292 0.516 0.338 0.716 0.134 0.381 0.507 -0.335 0.500 0.288 0.365 0.770 0.492 0.865
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Table 4 (Continued)
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23
Residual
Q1 0.000 0.000 0.167 -0.184 -0.047 0.015 0.023 0.029 0.056 0.026 0.135 -0.072 0.016 -0.069 -0.008 -0.037 0.071 0.035 -0.047 0.082 0.000 -0.041
Q2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Q3 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
Q4 0.167 0.000 0.000 0.040 -0.068 0.014 -0.005 0.083 -0.154 -0.027 0.029 -0.111 0.003 0.112 -0.009 -0.124 -0.155 0.117 -0.109 0.056 0.000 0.027
Q5 -0.184 0.000 0.000 0.040 -0.090 0.137 0.101 0.033 -0.061 -0.011 -0.051 0.070 -0.002 -0.011 -0.004 0.051 0.015 0.008 -0.079 -0.025 0.000 0.024
Q6 -0.047 0.000 0.000 -0.068 -0.090 0.054 -0.013 -0.039 0.005 0.016 0.049 -0.042 -0.005 0.028 0.000 0.112 -0.178 -0.010 0.026 0.086 0.000 0.023
Q7 0.015 0.000 0.000 0.014 0.137 0.054 0.063 0.035 -0.130 0.033 0.079 -0.019 -0.060 0.049 -0.001 0.060 -0.055 0.094 -0.018 -0.050 0.000 0.000
Q8 0.023 0.000 0.000 -0.005 0.101 -0.013 0.063 0.016 0.091 -0.003 0.025 -0.095 -0.023 -0.045 0.001 -0.014 0.103 0.025 0.001 -0.061 0.000 0.021
Q9 0.029 0.000 0.000 0.083 0.033 -0.039 0.035 0.016 0.004 -0.016 0.054 0.028 -0.020 0.036 -0.002 -0.060 -0.082 -0.023 0.019 -0.008 0.000 -0.020
Q10 0.056 0.000 0.000 -0.154 -0.061 0.005 -0.130 0.091 0.004 0.024 0.153 -0.072 0.056 -0.106 0.002 0.069 0.139 0.001 0.012 0.066 0.000 -0.013
Q11 0.026 0.000 0.000 -0.027 -0.011 0.016 0.033 -0.003 -0.016 0.024 -0.061 -0.024 -0.018 0.021 0.000 -0.036 0.031 0.020 0.014 -0.035 0.000 0.006
Q12 0.135 0.000 0.000 0.029 -0.051 0.049 0.079 0.025 0.054 0.153 -0.061 -0.031 0.074 -0.069 -0.003 0.024 -0.061 -0.038 -0.060 0.140 0.000 -0.022
Q13 -0.072 0.000 0.000 -0.111 0.070 -0.042 -0.019 -0.095 0.028 -0.072 -0.024 -0.031 -0.021 0.070 0.001 -0.026 0.045 -0.059 -0.015 0.025 0.000 0.005
Q14 0.016 0.000 0.000 0.003 -0.002 -0.005 -0.060 -0.023 -0.020 0.056 -0.018 0.074 -0.021 0.018 0.001 0.068 -0.042 -0.022 0.002 0.039 0.000 0.014
Q15 -0.069 0.000 0.000 0.112 -0.011 0.028 0.049 -0.045 0.036 -0.106 0.021 -0.069 0.070 0.018 -0.002 -0.026 -0.089 0.015 -0.032 -0.015 0.000 0.001
Q16 -0.008 0.000 0.000 -0.009 -0.004 0.000 -0.001 0.001 -0.002 0.002 0.000 -0.003 0.001 0.001 -0.002 0.001 0.003 0.000 0.001 0.003 0.000 0.000
Q17 -0.037 0.000 0.000 -0.124 0.051 0.112 0.060 -0.014 -0.060 0.069 -0.036 0.024 -0.026 0.068 -0.026 0.001 -0.001 -0.035 0.011 0.108 0.000 0.016
Q18 0.071 0.000 0.001 -0.155 0.015 -0.178 -0.055 0.103 -0.082 0.139 0.031 -0.061 0.045 -0.042 -0.089 0.003 -0.001 0.056 0.076 -0.028 0.000 -0.052
Q19 0.035 0.000 0.000 0.117 0.008 -0.010 0.094 0.025 -0.023 0.001 0.020 -0.038 -0.059 -0.022 0.015 0.000 -0.035 0.056 0.020 -0.038 0.000 0.004
Q20 -0.047 0.000 0.000 -0.109 -0.079 0.026 -0.018 0.001 0.019 0.012 0.014 -0.060 -0.015 0.002 -0.032 0.001 0.011 0.076 0.020 -0.023 0.000 0.007
Q21 0.082 0.000 0.000 0.056 -0.025 0.086 -0.050 -0.061 -0.008 0.066 -0.035 0.140 0.025 0.039 -0.015 0.003 0.108 -0.028 -0.038 -0.023 0.000 0.035
Q22 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Q23 -0.041 0.000 0.000 0.027 0.024 0.023 0.000 0.021 -0.020 -0.013 0.006 -0.022 0.005 0.014 0.001 0.000 0.016 -0.052 0.004 0.007 0.035 0.000
four, five, 13, 20, 21, and 23 (Table 6). The instrument in this 
study showed that the intervention group had a significantly 
higher patient satisfaction compared to the control group 
(88.10±5.87 versus 61.87±8.76; P0.05). Thus, the SQOP was 
able to discriminate between a group with higher satisfaction 
and lower satisfaction. This also demonstrated that the inter-
vention had an effect on participants’ satisfaction level.
comparison of the sQOP with other 
validated instruments
The psychometric properties of the SQOP were similar to 
that of other validated instruments for measuring patient 
satisfaction (Table 7).
Discussion
The SQOP performed satisfactorily in both the EFA and 
psychometric properties. This indicates that the SQOP is suit-
able to assess patients’ satisfaction towards an osteoporosis 
screening and prevention service in Malaysia.
EFA showed that there were seven domains of satisfac-
tion being measured within the main component to assess 
patients’ satisfaction towards an osteoporosis screening 
and prevention program in Malaysia. This was as expected 
as the researchers initially designed this tool to assess 
seven domains, namely outcomes/efficacy, accessibility/
convenience, technical quality, interpersonal relationship, 
finance, physical condition, and continuity. The seven 
domains were deemed to be significant to assess patients’ 
satisfaction as they concurred with the themes from a previ-
ous qualitative study.4
The domains measured by SQOP were then compared 
to that of other satisfaction tools related to osteoporosis. For 
example, the OPSQ measured convenience, time, trust, and 
usefulness of the counseling session.19 The Osteoporosis 
Patient Treatment Satisfaction Questionnaire measured 
convenience, confidence with daily activities, side effects, 
and overall satisfaction.18 The Preference and Satisfaction 
Questionnaire on the other hand measured preference, bother, 
and satisfaction.17 It was difficult to compare the domains of 
the Osteoporosis Patient Treatment Satisfaction Question-
naire, Preference and Satisfaction Questionnaire, and OPSQ 
as these tools were targeted at osteoporosis treatment instead 
of prevention. However, there were similarities in terms of 
some of the domains measured such as convenience and 
usefulness.
Corrected item-total correlations showed that all items mea-
sured the same main component – satisfaction. SQOP was 
designed as a multidimensional tool, rendering an overall 
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Table 4 (Continued)
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23
Residual
Q1 0.000 0.000 0.167 -0.184 -0.047 0.015 0.023 0.029 0.056 0.026 0.135 -0.072 0.016 -0.069 -0.008 -0.037 0.071 0.035 -0.047 0.082 0.000 -0.041
Q2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Q3 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000
Q4 0.167 0.000 0.000 0.040 -0.068 0.014 -0.005 0.083 -0.154 -0.027 0.029 -0.111 0.003 0.112 -0.009 -0.124 -0.155 0.117 -0.109 0.056 0.000 0.027
Q5 -0.184 0.000 0.000 0.040 -0.090 0.137 0.101 0.033 -0.061 -0.011 -0.051 0.070 -0.002 -0.011 -0.004 0.051 0.015 0.008 -0.079 -0.025 0.000 0.024
Q6 -0.047 0.000 0.000 -0.068 -0.090 0.054 -0.013 -0.039 0.005 0.016 0.049 -0.042 -0.005 0.028 0.000 0.112 -0.178 -0.010 0.026 0.086 0.000 0.023
Q7 0.015 0.000 0.000 0.014 0.137 0.054 0.063 0.035 -0.130 0.033 0.079 -0.019 -0.060 0.049 -0.001 0.060 -0.055 0.094 -0.018 -0.050 0.000 0.000
Q8 0.023 0.000 0.000 -0.005 0.101 -0.013 0.063 0.016 0.091 -0.003 0.025 -0.095 -0.023 -0.045 0.001 -0.014 0.103 0.025 0.001 -0.061 0.000 0.021
Q9 0.029 0.000 0.000 0.083 0.033 -0.039 0.035 0.016 0.004 -0.016 0.054 0.028 -0.020 0.036 -0.002 -0.060 -0.082 -0.023 0.019 -0.008 0.000 -0.020
Q10 0.056 0.000 0.000 -0.154 -0.061 0.005 -0.130 0.091 0.004 0.024 0.153 -0.072 0.056 -0.106 0.002 0.069 0.139 0.001 0.012 0.066 0.000 -0.013
Q11 0.026 0.000 0.000 -0.027 -0.011 0.016 0.033 -0.003 -0.016 0.024 -0.061 -0.024 -0.018 0.021 0.000 -0.036 0.031 0.020 0.014 -0.035 0.000 0.006
Q12 0.135 0.000 0.000 0.029 -0.051 0.049 0.079 0.025 0.054 0.153 -0.061 -0.031 0.074 -0.069 -0.003 0.024 -0.061 -0.038 -0.060 0.140 0.000 -0.022
Q13 -0.072 0.000 0.000 -0.111 0.070 -0.042 -0.019 -0.095 0.028 -0.072 -0.024 -0.031 -0.021 0.070 0.001 -0.026 0.045 -0.059 -0.015 0.025 0.000 0.005
Q14 0.016 0.000 0.000 0.003 -0.002 -0.005 -0.060 -0.023 -0.020 0.056 -0.018 0.074 -0.021 0.018 0.001 0.068 -0.042 -0.022 0.002 0.039 0.000 0.014
Q15 -0.069 0.000 0.000 0.112 -0.011 0.028 0.049 -0.045 0.036 -0.106 0.021 -0.069 0.070 0.018 -0.002 -0.026 -0.089 0.015 -0.032 -0.015 0.000 0.001
Q16 -0.008 0.000 0.000 -0.009 -0.004 0.000 -0.001 0.001 -0.002 0.002 0.000 -0.003 0.001 0.001 -0.002 0.001 0.003 0.000 0.001 0.003 0.000 0.000
Q17 -0.037 0.000 0.000 -0.124 0.051 0.112 0.060 -0.014 -0.060 0.069 -0.036 0.024 -0.026 0.068 -0.026 0.001 -0.001 -0.035 0.011 0.108 0.000 0.016
Q18 0.071 0.000 0.001 -0.155 0.015 -0.178 -0.055 0.103 -0.082 0.139 0.031 -0.061 0.045 -0.042 -0.089 0.003 -0.001 0.056 0.076 -0.028 0.000 -0.052
Q19 0.035 0.000 0.000 0.117 0.008 -0.010 0.094 0.025 -0.023 0.001 0.020 -0.038 -0.059 -0.022 0.015 0.000 -0.035 0.056 0.020 -0.038 0.000 0.004
Q20 -0.047 0.000 0.000 -0.109 -0.079 0.026 -0.018 0.001 0.019 0.012 0.014 -0.060 -0.015 0.002 -0.032 0.001 0.011 0.076 0.020 -0.023 0.000 0.007
Q21 0.082 0.000 0.000 0.056 -0.025 0.086 -0.050 -0.061 -0.008 0.066 -0.035 0.140 0.025 0.039 -0.015 0.003 0.108 -0.028 -0.038 -0.023 0.000 0.035
Q22 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Q23 -0.041 0.000 0.000 0.027 0.024 0.023 0.000 0.021 -0.020 -0.013 0.006 -0.022 0.005 0.014 0.001 0.000 0.016 -0.052 0.004 0.007 0.035 0.000
Cronbach’s α unsuitable. Hence, Cronbach’s α was con-
ducted for each domain. The physical and technical quality 
domains had a low Cronbach’s α of 0.531 and 0.535, respec-
tively, due to the small number of items in each domain.24 
Nonetheless, the other two domains had an acceptable and 
good Cronbach’s α of 0.661 (accessibility/convenience) and 
0.812 (outcomes/efficacy).24 However, Cronbach’s α was not 
computed for the interpersonal relationship, continuity, and 
finance domains as these domains only had one item. These 
domains comprise a total of four items out of the 23 items. 
Flesch reading ease was satisfactory at 62.9 as this represents 
the standard reading level of documents for adults.
The SQOP performed satisfactorily at test–retest, indi-
cating that the SQOP achieved stable reliability. Only item 
five and item six were significantly different at test–retest 
for control participants. This may be because participants 
may have been more “satisfied with the service” provided 
by the pharmacist.
As for the intervention group, there was no significant 
difference in item scores between test and retest except for 
items four, five, 13, 20, 21, and 23. Item four was regard-
ing the comfort of the location. This difference may be due 
to participants having more time to reflect on the program 
and realizing that they were “more satisfied”, leading them 
to view the overall comfort more positively. Item five was 
regarding whether participants would ask the pharmacist if 
they had any questions about osteoporosis. Several of the 
participants changed to a more positive answer during the 
retest and this may be because of their intervention experi-
ence with the researcher who is a pharmacist. Items 13, 
20, 21, and 23 were regarding the amount of information 
provided, explanation of consequences of untreated osteo-
porosis, explanation on how osteoporosis can be prevented 
via lifestyle changes, and osteoporosis booklet provided, 
respectively. A possible explanation for this positive change 
could be because participants may have had more time to 
consider the information provided, found it useful, and hence 
were more satisfied. This in turn improved the overall score 
for the intervention participants significantly.
The SQOP was able to differentiate between patients 
who were expected to be more satisfied as they received an 
additional service (ie, the intervention) compared to those 
who did not receive the intervention, indicating that the items 
in SQOP were specific in addressing the different attributes 
of patients’ satisfaction towards an osteoporosis screening 
and prevention service in Malaysia.
Currently, there are only a limited number of studies that have 
validated instruments to measure patient satisfaction.17–19,25–28 
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Table 5 Psychometric properties of the satisfaction Questionnaire for Osteoporosis Prevention
Items Questions Corrected item-total 
correlation
Cronbach’s α 
if item deleted
Cronbach’s α Domains
1 The service was conducted at a time that _______ 
(fill in the blank) for you
0.508 0.527 0.661 Accessibility/
convenience
2 During the session, what did you think about the 
time given to discuss your problems with the 
pharmacist?
0.486 0.549
3 how would you rate the location of this service? 0.432 0.618
4 how would you rate the comfort of the location? 0.363 – 0.531 Physical
12 if you have questions about osteoporosis, would 
you ask the pharmacist?
0.363 –
5 Was the pharmacist easy to talk to? 0.378 – 0.535 Technical quality
9 how would you rate the service provided by the 
pharmacist?
0.378 –
6* how would you rate the advice given by the 
pharmacist?
interpersonal 
relationship
7 how would you rate the overall quality of service 
that was given by the pharmacist to you?
0.439 0.801 0.812 Outcomes/
efficacy
8 This pharmacist service should _______  
(fill in the blank)
0.426 0.803
10 What do you think about having the same 
pharmacist to see you for subsequent osteoporosis 
care?
0.263 0.813
13 Pharmacist in other hospitals should ______  
(fill in the blank) this service
0.574 0.788
14 how would you rate the amount of information 
provided to prevent falls?
0.500 0.797
15 how would you rate the amount of information 
provided to change your diet to prevent bone loss?
0.480 0.799
18 how would you rate the amount of information 
provided on the exercises to help strengthen 
bones?
0.551 0.791
19 Would you pay for a pharmacist counseling 
service?
0.421 0.802
20 if yes, how much are you willing to pay for each 
visit to the pharmacist? if you are not willing to 
pay anything for the service, please proceed to 
question 18
0.509 0.794
21 how would you rate your understanding of 
osteoporosis now?
0.440 0.801
22 explanation of osteoporosis 0.446 0.800
23 explanation of consequences of untreated 
osteoporosis
0.543 0.793
11* explanation on how osteoporosis can be prevented 
via lifestyle change(s)
continuity
16* explanation on the available methods to screen for 
osteoporosis
Finance
17# Osteoporosis booklet provided
Notes: *There was only one item in these domains, hence cronbach’s α could not be conducted. #This was an optional question, hence it was excluded from the calculation 
of cronbach’s α. 
The psychometric properties of the SQOP were similar to 
previous satisfaction tools.
A limitation of this study was that SPSS Amos (IBM) 
was not used to conduct confirmatory factor analysis as 
five of the seven domains were developed with two items 
or less (finance, physical condition, interpersonal relation-
ship, continuity, and technical quality). This was because 
the questionnaire was designed so that participants would 
only take approximately 5 minutes to complete, to ensure 
the practicality of its usage in daily practice. The number 
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Table 6 Test and retest reliability of the satisfaction Questionnaire for Osteoporosis Prevention
Items Control group Spearman’s 
correlation 
test*
Test (n=70) Retest (n=70) Wilcoxon–signed rank test
Mean ± SD Median Mean ± SD Median Mean/rank z score P-value
1 3.17±0.72 3.00 3.13±0.78 3.00 4.00/4.00 -1.134 0.257 0.938
2 2.90±0.98 3.00 2.91±1.03 3.00 1.00/2.00 -0.447 0.655 0.978
3 3.73±1.23 4.00 3.74±1.21 5.00 4.00/4.00 -0.378 0.705 0.949
4 3.59±1.17 4.00 3.63±1.17 5.00 9.33/8.00 -0.688 0.491 0.877
5 3.26±1.37 3.00 3.31±1.37 4.25 0.00/2.50 -2.000 0.046* 0.983
6 3.49±1.13 4.00 3.23±1.22 4.00 8.32/4.50 -2.508 0.012* 0.745
7 3.59±0.81 4.00 3.63±0.85 4.00 3.00/3.00 -1.342 0.180 0.958
8 3.29±0.95 3.00 3.13±1.06 4.00 8.61/5.50 -1.639 0.101 0.726
9 3.14±0.97 3.00 3.11±0.93 4.00 3.50/3.50 -0.816 0.414 0.955
10 3.36±0.84 3.00 3.41±0.83 4.00 3.50/5.10 -1.100 0.271 0.908
11 3.91±1.03 4.00 3.86±0.92 5.00 5.25/4.50 1.155 0.248 0.925
12 3.33±0.78 3.00 3.33±0.78 3.25 1.50/1.50 0.000 1.000 0.996
13 2.41±1.10 3.00 2.31±0.96 3.00 11.09/8.50 -1.170 0.242 0.802
14 2.20±0.97 2.00 2.19±1.01 3.00 9.00/8.00 -0.229 0.819 0.862
15 2.20±0.97 2.50 2.13±0.95 3.00 11.82/12.28 -0.923 0.356 0.796
16 2.01±1.35 1.00 1.99±1.29 3.00 3.33/2.50 -0.707 0.480 0.947
17 3.25±1.71 4.00 3.73±1.61 5.00 0.00/1.00 -1.000 0.317 0.726
18 3.01±0.12 3.00 3.00±0.00 3.00 1.00/0.00 -1.000 0.317 0.981
19#
20#
21#
22#
23#
Total 61.87±8.76 61.18 61.23±8.96 61.77 29.79/24.41 -1.580 0.114 0.941
Items Intervention group Spearman’s 
correlation 
test
Test (n=70) Retest (n=62) Wilcoxon–signed rank test
Mean ± SD Median Mean ± SD Median Mean/rank t-value P-value
1 4.49±0.79 5.00 4.55±0.92 5.00 7.50/5.00 -1.387 0.166 0.818
2 4.47±0.85 5.00 4.50±0.99 5.00 4.50/4.50 -1.414 0.157 0.849
3 4.67±0.76 5.00 4.69±0.78 5.00 3.50/3.50 -0.816 0.414 0.868
4 4.49±0.68 5.00 4.63±0.73 5.00 5.50/5.50 -2.530 0.011* 0.794
5 4.27±1.01 5.00 4.35±0.98 5.00 0.00/3.50 -2.333 0.020* 0.900
6 4.97±0.17 5.00 4.97±0.18 5.00 1.50/1.50 0.000 1.000 0.483
7 4.60±0.49 5.00 4.68±0.47 5.00 4.00/4.00 -1.890 0.059 0.769
8 4.83±0.38 5.00 4.84±0.37 5.00 2.50/2.50 0.000 1.000 0.762
9 4.31±0.60 4.00 4.39±0.58 4.00 3.00/3.60 -1.667 0.096 0.815
10 4.81±0.46 5.00 4.79±0.48 5.00 2.50/2.50 0.000 1.000 0.794
11 4.51±0.78 5.00 4.42±0.90 5.00 2.50/1.00 -1.069 0.285 0.910
12 4.66±0.66 5.00 4.69±0.64 5.00 3.00/3.00 -1.342 0.180 0.822
13 4.43±0.75 5.00 4.50±0.74 5.00 0.00/3.50 -2.449 0.014* 0.869
14 4.40±0.75 5.00 4.45±0.74 5.00 5.50/5.50 -1.265 0.206 0.751
15 4.46±0.76 5.00 4.47±0.76 5.00 2.50/2.50 -1.000 0.317 0.915
16 2.76±1.47 3.00 2.28±1.48 3.00 0.00/1.00 -1.000 0.317 0.967
17 3.25±1.48 4.00 3.23±1.42 3.50 1.00/0.00 -1.000 0.317 0.987
18 4.64±0.54 5.00 4.69±0.50 5.00 0.00/2.00 -1.732 0.083 0.929
19 4.20±4.67 4.00 4.29±0.49 4.00 3.50/3.50 -1.633 0.102 0.785
20 4.06±0.59 4.00 4.19±0.62 4.00 6.00/6.00 -2.111 0.035* 0.798
21 4.26±0.50 4.00 4.37±0.52 4.00 4.50/5.06 -2.309 0.021* 0.699
22 4.19±0.55 4.00 4.23±0.64 4.00 3.50/3.50 -1.633 0.102 0.849
23 4.44±0.50 4.00 4.77±0.42 5.00 0.00/11.50 -4.690 0.000* 0.459
Total 88.10±5.87 88.18 89.36±5.98 89.09 13.79/25.79 -4.995 0.000* 0.948
Notes: *Statistically significant at P0.05. **item 17 was excluded from the total score calculation as it was an optional question. #The control group was not required to 
answer items 19–23 as these items were specifically assessing the satisfaction of the intervention conducted.
Abbreviation: sD, standard deviation.
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Table 7 comparison of psychometric properties of the satisfaction Questionnaire for Osteoporosis Prevention to other validated 
patient satisfaction instruments
SQOP OPSQ19 OPSAT-Q18 PSQ17 PSQ-An28 DMET26 DDSM-Q25 PEQD27
number of subjects 140 180 104 1,583 312 202 114 1,472
Age,* years 59.5±7.2 65.6±9.3 65.1±10.3 65.4 60.2±11.8 55.7 61.9±9.4 51.0±16.0
Type of study rcT rcT Observational rcT Observational Observational Observational rcT
number of items 23 16 16 20 11 73 31 12
number of domains 7 2 4 6 2 2 3 4
cronbach’s α 0.81 0.86 0.72–0.89 0.61–0.93 0.83 0.79–0.95 – 0.73–0.84
Factor analysis: number 
of components
7 1 – 5 – 13 3 –
number of times 
administered
Twice Once Twice Once Twice Once Once Twice 
(n=202)
interval between 
administration
2 weeks nA 2 weeks nA 4 weeks nA nA 66±14 
days*
Test–retest reliability: 
intraclass correlation
0.46–0.98 nA 0.62–0.81 nA 0.45–0.67 nA nA 0.66–0.83
Note: *Data are presented as mean ± standard deviation.
Abbreviations: DDsM-Q, Diabetes Disease state Management Questionnaire; DMeT, Diabetes Management evaluation tool; nA, not applicable; OPsAT-Q, Osteoporosis 
Patient Treatment satisfaction Questionnaire; OPsQ, Osteoporosis Patient satisfaction Questionnaire; PeQD, Patients’ evaluation of the Quality of Diabetes care; PsQ, 
Preference and satisfaction Questionnaire; PsQ-An, Patient satisfaction Questionnaire for Anemia Treatment; rcT, randomized controlled trial; sQOP, satisfaction 
Questionnaire for Osteoporosis Prevention.
of items per domain was determined based on the patients’ 
emphasis towards the domain during the in-depth interviews. 
Nonetheless, EFA showed that there were seven components 
measuring the patients’ satisfaction.
Another limitation of this study was that SQOP was 
designed to measure the satisfaction of patients towards a 
pharmacist-conducted osteoporosis screening and prevention 
service. Hence, wordings such as “Was the pharmacist easy to 
talk to?” was used. Hence, the implementation of this question-
naire is limited to services provided by a pharmacist. Minor 
modifications of the SQOP will be required if used to assess 
satisfaction provided by other health care professionals.
Participants in this study were mainly Chinese (42.9%) 
and Indians (30.7%). This does not represent the ethnic 
distribution of Malaysia. It only represents the ethnicity of 
patients who sought treatment at the study site, meaning that 
the results cannot be considered population based. Future 
validation studies of the tool to Malay and Mandarin, and 
enrollment of participants from multiple sites would be more 
representative of the Malaysian population.
Conclusion
The English version of the SQOP was found to be a reliable 
and valid instrument for assessing patients’ satisfaction 
towards an osteoporosis screening and prevention program in 
Malaysia. Future studies should include the translation of the 
SQOP into Malay and Mandarin to assess patient satisfaction 
for Malaysians that are not fluent in English.
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Supplementary material
The full questionnaire of the English version of the Satisfaction Questionnaire for Osteoporosis Prevention.
Satisfaction Questionnaire for Osteoporosis Prevention (SQOP)  self/assisted 
This questionnaire is to assess your satisfaction about a pharmacist-conducted osteoporosis prevention program. Filling out 
this questionnaire will provide information for us to further improve our services.
Please tick the answer that best suits your opinion.
A. Clinical services
1. The service was conducted at a time that_______  
(fill in the blank) for you
 
5
Was definitely suitable
 
4
Was probably suitable
 
3
Made no difference
 
2
Was probably unsuitable
 
1
Was definitely unsuitable
2. During the session, what did you think  
about the time given to discuss your  
problems with the pharmacist?
 
5
Definitely enough time
 
4
Probably enough time
 
3
No difference
 
2
Probably insufficient time
 
1
Definitely insufficient time
3. How would you rate the location of this  
service?
 
5
Very convenient
 
4
Somewhat convenient
 
3
No difference
 
2
Somewhat inconvenient
 
1
Very inconvenient 
4. How would you rate the comfort of the  
location? 
 
5
Very comfortable
 
4
Somewhat comfortable
 
3
No difference
 
2
Somewhat uncomfortable
 
1
Very uncomfortable
5. If you have questions about osteoporosis,  
would you ask the pharmacist?
 
5 
Yes, I would definitely trust the 
answer given by the pharmacist
 
4 
Yes, I would probably trust the 
answer given by the pharmacist
 
3
No comment
 
2 
No, I probably would not trust the 
answer given by the pharmacist
 
1 
No, I definitely would not trust the 
answer given by the pharmacist
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6. Was the pharmacist easy to talk to?  
5
Definitely approachable
 
4
Probably approachable
 
3
No difference
 
2
Probably unapproachable
 
1
Definitely unapproachable
7. How would you rate the service provided  
by the pharmacist?
 
5
Definitely useful
 
4
Useful
 
3
No difference
 
2
Not useful
 
1
Definitely not useful 
8. How would you rate the advice given by the pharmacist?  
5
Definitely helpful
 
4
Probably helpful
 
3
No difference
 
2
Probably not helpful
 
1
Definitely not helpful at all
9. How would you rate the overall quality of service that was 
given by the pharmacist to you?
 
5
Excellent
 
4
Good
 
3
Satisfactory
 
2
Fair
 
1
Poor
10. This pharmacist service should _______ (fill in the blank)  
5
Definitely be continued
 
4
Probably be continued
 
3
No comment
 
2
Probably be discontinued
 
1
Definitely be discontinued
11. What do you think about having the same pharmacist to see 
you for subsequent osteoporosis care?
 
5
Yes, I would definitely like that
 
4
Yes, I would probably like that
 
3
No difference
 
2
No, I probably would not like that
 
1
No, I definitely would not like that
12. Pharmacist in other hospitals should ______ (fill in the blank) 
this service
 
5
Definitely provide
 
4
Probably provide
 
3
No comment
 
2
Probably not provide
 
1
Definitely not provide
13. How would you rate the amount of information provided to 
prevent falls?
 
5
Definitely enough
 
4
Probably enough
 
3
No difference
 
2
Probably not enough
 
1
Definitely not enough
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14. How would you rate the amount of information provided to 
change your diet to prevent bone loss?
 
5
Definitely enough
 
4
Probably enough
 
3
No difference
 
2
Probably not enough
 
1
Definitely not enough
15. How would you rate the amount of information provided on 
the exercises to help strengthen bones?
 
5
Definitely enough
 
4
Probably enough
 
3
No difference
 
2
Probably not enough
 
1
Definitely not enough
16. Would you pay for a pharmacist counseling service?  
5
Yes, definitely
 
4
Yes, probably
 
3
No difference
 
2
No, probably not
 
1
No, definitely not
17. If yes, how much are you willing to pay for each visit to the 
pharmacist?
If you are not willing to pay anything for the service, please 
proceed to question 18
 
5
RM1–5
 
4
RM6–10
 
3
RM11–15
 
2
RM16–20
 
1
More than RM20
18. How would you rate your understanding of osteoporosis 
now?
 
5
Much better than before
 
4
Slightly better than before
 
3
Same as before
 
2
Slightly worse than before
 
1
Much worse than before
B. Types of counseling
Please indicate how you found the following information which the pharmacist may have provided. If you were not provided 
with any counseling, please omit this section.
19. Explanation of osteoporosis  
0
Not applicable
 
1
Definitely not useful
 
2
Not useful
 
3
No difference
 
4
Useful
 
5
Extremely useful 
20. Explanation of consequences of untreated osteoporosis  
0
Not applicable
 
1
Definitely not useful
 
2
Not useful
 
3
No difference
 
4
Useful
 
5
Extremely useful 
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21. Explanation on how osteoporosis can be prevented via life-
style change(s)
 
0
Not applicable
 
1
Definitely not useful
 
2
Not useful
 
3
No difference
 
4
Useful
 
5
Extremely useful 
22. Explanation on the available methods to screen for 
osteoporosis 
 
0
Not applicable
 
1
Definitely not useful
 
2
Not useful
 
3
No difference
 
4
Useful
 
5
Extremely useful 
23. Osteoporosis booklet provided  
0
Not applicable
 
1
Definitely not useful
 
2
Not useful
 
3
No difference
 
4
Useful
 
5
Extremely useful 
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